Pulmonary Arterial Hypertension: From Molecular Basis to Therapeutic Approaches

Dear Colleagues,

Pulmonary arterial hypertension (PAH) continues to be a condition associated with high morbidity and mortality. Currently available treatments for PAH were developed to restore an imbalance of vasoactive factors. These traditional medications include the prostacyclin analogs and receptor agonists, phosphodiesterase 5 inhibitors, endothelin receptor antagonists and cGMP activators.

However, progress observed in the medical therapy of PAH patients over the past 15 years is not related to the discovery of new pathways, but to the evolution and testing of new drugs and strategies for combination therapy, and the escalation of treatments based on a systematic assessment of clinical response. These medications prolong life, but mortality remains unacceptably high. Although PAH is a disorder of pulmonary vasculature, right ventricle function is the main prognostic marker and should therefore also be the focus of a more detailed analysis for new drug development in PAH.

This Special Issue will pay attention to the recent advances in PAH research. We encourage investigators to submit original (basic and translational) research articles and reviews to this Special Issue with the purpose to address mechanistic insights and decipher novel diagnostic tools and new treatments for PAH.

Topics include, but are not limited to:

• Cellular, molecular and/or hemodynamic mechanisms that drive PAH;
• The role of epigenetics in the pathogenesis of PAH;
• Potential new treatments for PAH;
• Repurposing established drugs for the resolution of PAH;
• New perspectives on direct therapies for right heart failure in PAH.

Dr. Rui Adão
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pulmonary arterial hypertension
• right ventricle
• right heart failure
• therapy
• vascular disease
• translational research